AUTHORS
Alberto Guijosa, MD, Grace M Ferri, MD2, Nicolò Danesin, MD3, Nickolas Tsakmaklis4, Joshua Gustine, MD, MPH5, Margaret Kobs, NP6, Amanda Kofides, MSc7, Maria Luisa Guerrera, MD8, Camille Edwards, MD9, Tarek Mouhieddine, MD10, Zachary R Hunter, PhD11, Steven Treon, MD, PhD12, Shayna Sarosiek, MD13, Gottfried von Keudell, MD14, Andrew Branagan, MD, PhD15, Jorge J Castillo, MD16
AFFILIATIONS
1 Brigham and Women's Hospital, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
2 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, University of Padova, Padova, Italy
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
8 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
10 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
11 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
12 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
14 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
15 Massachusetts General Hospital, Boston, United States
16 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
ABSTRACT
Introduction: Patients with non-IgM lymphoplasmacytic lymphoma (LPL) have been systematically excluded from Waldenström macroglobulinemia (WM) clinical trials, leaving its biology and optimal treatment poorly defined. The IWWM-12 consensus panel recommended managing non-IgM LPL following WM guidelines, based mostly on expert opinion and limited data. We conducted the largest multicenter study to date to characterize non-IgM LPL’s clinicopathologic and genomic features, compare first-line treatment outcomes, and benchmark Bruton tyrosine kinase inhibitor (BTKi) efficacy against WM.
Methods: We identified consecutive patients with bone marrow-confirmed non-IgM LPL evaluated at Dana-Farber Cancer Institute, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center between 2005 and 2025. MYD88, CXCR4, and TP53 were assessed by allele-specific PCR (AS-PCR), Sanger sequencing, or next-generation sequencing (NGS), with a 52-patient subset undergoing uniform targeted NGS. Cytogenetics used G-banded karyotyping. Responses followed IWWM-12 criteria. BTKi recipients were matched 1:3 by exact matching (agent, line, age, treatment year) to BTKi-treated WM patients. Time-to-event outcomes were estimated by Kaplan-Meier and compared by log-rank test; multivariable logistic and Cox models were adjusted for sex and age.
Results: Among 139 patients (IgG 97 [70%], IgA 27 [19%], non-secretory 13 [9%], light chain-only 2 [1%]), median age was 64 years and median follow-up 5.5 years. MYD88 was mutated in 100/113 tested patients (89%) overall but in 57/60 (95%) tested by guideline-recommended AS-PCR. CXCR4 was mutated in 21/68 (31%) and TP53 in 4/68 (6%), with del(17p) in 1/61 (2%). del(6q) was the most common cytogenetic abnormality (10/105 [10%]). In the 52-patient NGS subset, MYD88 (65%) and CXCR4 (23%) were the most frequent mutations, with DNMT3A (15%) and TET2 (10%) consistent with clonal hematopoiesis.
Compared with IgG LPL, IgA LPL had higher rates of hyperviscosity (15% vs 1%; p=0.001), Bing-Neel syndrome (15% vs 2%; p=0.006), pleural effusions (15% vs 2%; p=0.006), and histologic transformation (7% vs 1%; p=0.056). Five-year overall survival (OS; 86% vs 93%; p=0.054) and survival after first-line treatment initiation (SAFTI; 82% vs 91%; p=0.080) were lower in IgA LPL, which remained independently associated with inferior SAFTI (HR 2.88; 95% CI 1.03-8.02; p=0.044) after adjusting for age and sex.
Of 105 treated patients (76%), median time from diagnosis to treatment was 10.7 months and median follow-up from first-line initiation was 5.2 years. Overall response rate was 55/79 (70%), with major response in 42/79 (53%); median PFS, TTNT, and SAFTI were 4.7, 5.1, and 18.9 years. Among the four most common first-line regimens, BTKi (n=24) and bendamustine-rituximab (BR; n=26) produced the best outcomes compared with rituximab monotherapy (R; n=33) and cyclophosphamide-based regimens (Cy; n=9). VGPR or better was achieved in 45%, 60%, 19%, and 38%, respectively (p=0.061). Three-year PFS was 92%, 69%, 39%, and 56% (p<0.001), and 3-year TTNT was 88%, 86%, 45%, and 56%, respectively (p<0.001). In multivariable analysis, BTKi and BR independently improved PFS and TTNT versus R (p≤0.006). Three-year SAFTI did not differ across regimens (p=0.322).
Among 49 BTKi recipients (24 frontline, 25 relapsed/refractory), VGPR or better was 17/38 (45%), with 3-year PFS, TTNT, and OS of 91%, 76%, and 95%. In the 1:3 matched analysis (41 non-IgM LPL vs 123 WM), VGPR or better (47% vs 33%; p=0.155), 3-year PFS (91% vs 82%; p=0.165), TTNT (78% vs 66%; p=0.429), and OS (97% vs 95%; p=0.509) were comparable.
Conclusions: In the largest cohort reported to date, non-IgM LPL closely resembles WM in its genomic drivers and treatment responsiveness, with principal clinical differences driven by immunoglobulin isotype. IgA LPL emerged as a higher-risk subgroup, with more disease-related complications and inferior survival after treatment initiation. BTKi- and BR-based therapies provided superior disease control over R and Cy, with BTKi outcomes equivalent to matched WM patients. These findings provide the first evidence base for treatment selection in non-IgM LPL and support extending WM-directed therapies and clinical trials to this historically excluded population.
DISCLOSURES
Alberto Guijosa, MD: No relevant conflicts of interest to declare.